Skip to main content
. 2012 Aug 16;6:287–303. doi: 10.4137/CMO.S8511

Figure 4.

Figure 4

Cumulative percent change in BMD from baseline, denosumab vs. placebo in men with prostate cancer receiving ADT.126

Notes: Results are presented as least-squares means.

Abbreviation: BMD, bone mineral density.